Last reviewed 2026-05-14 · How we verify

Osivax — Portfolio Competitive Intelligence Brief

Osivax pipeline: 0 marketed, 0 filed, 0 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

• Immunology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

1. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
3. Brigham and Women's Hospital · 1 shared drug class
4. Chiltern Pesquisa Clinica Ltda · 1 shared drug class
5. Fluart Innovative Vaccine Ltd, Hungary · 1 shared drug class
6. Folia Biotech Inc. · 1 shared drug class
7. GlaxoSmithKline · 1 shared drug class
8. Ab&B Bio-tech Co., Ltd.JS · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Osivax:

• Osivax pipeline updates — RSS
• Osivax pipeline updates — Atom
• Osivax pipeline updates — JSON

Cite this brief

Drug Landscape (2026). Osivax — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/osivax. Accessed 2026-05-14.

Related

• Osivax full company profile
• All CI briefs
• Build a custom feed